NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancer.

Breast Cancer Res · 2019 · PMC6892191 · PMID 31796073

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendP = 0.056so close (0.05 < p ≤ 0.1)

The pCR rate of the combined high and intermediate benefit groups (26/44), compared to the no benefit group (2/9), was higher (59% vs 22%) and showed a trend for significance ( P = 0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.